

SUPPLEMENTARY INFORMATION

Differential regulation of elastic fiber formation by fibulins -4 and -5

Rawshan Choudhury^{1#}, Amanda McGovern^{1#}, Caroline Ridley^{2#}, Stuart A. Cain¹, Andrew Baldwin¹, Ming-Chuan Wang¹, Chun Guo¹, Aleksandr Mironov Jnr.¹, Zoe Drymoussi¹, Dorothy Trump², Adrian Shuttleworth¹, Clair Baldock¹ and Cay M. Kielty^{1*}

[#]*Joint first authors*

¹Wellcome Trust Centre for Cell-Matrix Research, Faculty of Life Sciences, and ²Faculty of Medical and Human Sciences, University of Manchester, UK.

LEGENDS TO SUPPLEMENTARY FIGURES

FIGURE S1

SDS-PAGE analysis of recombinant fibulins -4 and -5, fibrillin-1 and LOX

The following proteins were expressed and analyzed by SDS-PAGE in the presence or absence of 10 mM dithiothreitol (R or NR, respectively), by Coomassie blue staining: full-length fibulin-4 (F4), C-terminally truncated fibulin-4 (tF4), the N-terminal half of fibulin-4 (nF4) and the five central cbEGFs (eF4); full-length fibulin-5 (F5) without or with two cutis laxa mutations (F5_{C217R} and F5_{S227P}), and domain pair fragments; fibrillin-1 fragments have previously been reported (not shown) (1-8) apart from a two-thirds fragment (tFib-1) which is shown by western blotting as a 250 kDa fragment using several anti-fibrillin-1 antibodies including (shown) fibrillin-1-specific RGD antibody (9); full-length lysyl oxidase (LOX). Treatment of F4 and tF4 with N-glycosidase F (PNGase F; indicated by arrows) resulted in slightly faster electrophoretic migration, indicating that both are N-glycosylated. Treatment of F5 and mutants, F5-E4+5, F5-E5+6 and F5-E6FC with N-glycosidase F also confirmed that they were N-glycosylated (not shown) (1,3). Fibrillin-1 fragments have been confirmed to be N-glycosylated.

FIGURE S2

Mass spectrometry of truncated fibulin-4 and fibrillin-1

(A) The peptide sequence coverage (shown in red text), as determined by mass spectrometry, of F4 and tF4. Truncated fibulin-4 tF4 lacks the FC domain and 6 preceding amino acid residues (for domain organization, *see* Fig. 1A).

(B) The peptide sequence coverage (shown in red text), as determined by mass spectrometry, of the two-thirds truncated fibrillin-1 fragment (tFib-1) (for domain organization, *see* Fig. 1B).

FIGURE S3

Multi-angle laser light scattering of human fibulins -4 and -5

Monomers of (i) fibulin-4 (F4) and (ii,iii) fibulin-5 (F5 and F5_{S227P}) that had been isolated by Superdex 200 gel filtration in HBS, were analyzed by MALLS in HBS. Samples eluting from the column passed through a Wyatt EOS 18-angle light scattering detector fitted with a 688 nm laser and an Optilab r-EX refractometer (*see* Table 1). F4 was monomeric in the absence of calcium, but formed dimers in the presence of calcium. Similarly, F5 and F5 mutant F5_{S227P} were

monomeric in the absence of calcium, but dimeric in the presence of calcium (not shown; Jones *et al*, in preparation).

FIGURE S4

Molecular interactions of fibulin-5, fibrillin-1 and tropoelastin

(A) Solid-phase assays of biotinylated fibulin-5 fragments binding to immobilized tropoelastin. Three of the domain pair fragments, F5-E1+2, F5-E4+5 and F5-E6FC bound well to immobilized tropoelastin (K_{Ds} 332 nM, 452 nM and 965 nM, respectively). One representative experiment is shown. Data are shown with the negative (biotinylated F5 fragments only) control subtracted. Results are shown as the mean \pm S.E. of triplicate values.

(B) Solid-phase curves showing soluble biotinylated fibulin-5 domain-pair fragments (F5-E1+2 or F5-E6FC) binding to immobilized PF1. These fibulin-5 fragments only bound N-terminal fibrillin-1. One representative experiment is shown. Data are shown with the negative (biotinylated F5 fragments only) control subtracted. Results are shown as the mean \pm S.E. of triplicate values.

(C) BIAcore analysis of soluble tFib-1 (200 nM) (C-terminally truncated two-thirds fragment of fibrillin-1; see Figure S1)) binding to immobilized tropoelastin. Response difference is the difference between experimental and control flow cells, in response units (RU). Pre-incubation of F5 with tFib-1 neither inhibited nor stimulated the binding of fibrillin-1 to tropoelastin (not shown).

(D) Fibrillin-1 (tFib-1) inhibits soluble F4 interacting with immobilized tropoelastin. BIAcore analysis of the interaction of soluble F4 with immobilized tropoelastin, showing that pre-incubation of F4 with tFib-1 (C-terminally truncated two-thirds fragment of fibrillin-1; see Figure S1) inhibits F4 binding to tropoelastin.

FIGURE S5

Elastic fiber molecules expressed by dermal fibroblasts, ARPE-19 cells and RFL6 cells

(A) (i) RT-PCR analysis of the expression of fibulins -4 and -5 by ARPE-19 cells. Fibulin-4 was expressed at moderate levels, but fibulin-5 expression was very low. (ii) Fibulin-4 was knocked down in ARPE-19 cells using siRNA. Quantitative PCR (qPCR) and immunoblot analysis (not shown) showed 70% knockdown of fibulin-4.

(B) The expression of N-terminally V5-tagged human elastin (E) by ARPE-19 cells, after retroviral induction, was detected on blots by anti-V5 antibody (Abcam) and by immunofluorescence microscopy (red) using a polyclonal anti-elastin antibody (PR398, Elastin Products Inc.), with DAPI (blue) staining of cell nuclei.

(C) Fibulin-5 was stably knocked down in RFL6 cells by retroviral shRNA. (i) RT-PCR and (ii, iii) qPCR, respectively, showed that fibulin-5 is depleted in the knockdown cells, compared to the scrambled control cells. qPCR also revealed that fibulin-4 is not altered in the fibulin-5 shRNA knockdown cells (not shown).

FIGURE S6

Effects of heparin on tropoelastin binding by fibulins -4 and -5

Heparin binds tropoelastin and influences its coacervation (Tu and Weiss, 2008). We examined whether heparin altered interactions of fibulins -4 and -5 with tropoelastin, by solid phase assays.

(A) (i) Pre-incubation of fibulins -4 or -5 with 10 nM or 100 nM heparin resulted in small but significant reductions in each fibulin binding to tropoelastin. A significant difference in binding of F4 or F5 to tropoelastin in the presence or absence of heparin was shown as ^{***}, $p < 0.001$ (unpaired t test). (ii) Increasing concentrations of heparin inhibited fibulin-4 binding to tropoelastin, but concentration-dependent heparin effects on fibulin-5 binding were less clear. In each case, one representative experiment is shown. Data are shown with the negative (biotinylated F4 or F5 only) control subtracted. Results are shown as the mean \pm S.E. of triplicate values.


(B) Pre-incubation of three fibulin-5 domain pair fragments that bind tropoelastin (see Fig. 2C) with heparin (both at 100 nM) resulted in significant reductions in fibulin binding to tropoelastin. Significant differences in binding of fibulin-5 domain pair fragments to tropoelastin in the presence or absence of heparin were shown as ^{*}, $p < 0.01$; ^{**}, $p < 0.05$; ^{***}, $p < 0.001$ (unpaired t test). In each case, one representative experiment is shown. Data are shown with the negative (biotinylated F5 fragments only) control subtracted. Results are shown as the mean \pm S.E. of triplicate values.

References

1. Freeman, L. J., Lomas, A., Hodson, N., Sherratt, M. J., Mellody, K. T., Weiss, A. S., Shuttleworth, A., and Kielty, C. M. (2005) *Biochem. J.* **388**, 1-5
2. Rock, M. J., Cain, S. A., Freeman, L. J., Morgan, A., Mellody, K., Marson, A., Shuttleworth, C. A., Weiss, A. S., and Kielty, C. M. (2004) *J. Biol. Chem.* **279**, 23748-23758
3. Lomas, A. C., Mellody, K. T., Freeman, L. J., Bax, D. V., Shuttleworth, C. A., and Kielty, C. M. (2007) *Biochem. J.* **405**, 417-428
4. Baldock, C., Siegler, V., Bax, D. V., Cain, S. A., Mellody, K. T., Marson, A., Haston, J. L., Berry, R., Wang, M. C., Grossmann, J. G., Roessle, M., Kielty, C. M., and Wess, T. J. (2006) *Proc. Natl. Acad. Sci. U. S. A* **103**, 11922-11927
5. Cain, S. A., Baldock, C., Gallagher, J., Morgan, A., Bax, D. V., Weiss, A. S., Shuttleworth, C. A., and Kielty, C. M. (2005) *J. Biol. Chem.* **280**, 30526-30537
6. Cain, S. A., Baldwin, A. K., Mahalingam, Y., Raynal, B., Jowitt, T. A., Shuttleworth, C. A., Couchman, J. R., and Kielty, C. M. (2008) *J. Biol. Chem.* **283**, 27017-27027
7. Marson, A., Rock, M. J., Cain, S. A., Freeman, L. J., Morgan, A., Mellody, K., Shuttleworth, C. A., Baldock, C., and Kielty, C. M. (2005) *J. Biol. Chem.* **280**, 5013-5021
8. Mellody, K. T., Freeman, L. J., Baldock, C., Jowitt, T. A., Siegler, V., Raynal, B. D., Cain, S. A., Wess, T. J., Shuttleworth, C. A., and Kielty, C. M. (2006) *J. Biol. Chem.* **281**, 31854-31862
9. Lee, S. S., Knott, V., Jovanovic, J., Harlos, K., Grimes, J. M., Choulier, L., Mardon, H. J., Stuart, D. I., and Handford, P. A. (2004) *Structure (Camb)* **12**, 717-729


Supplementary Figure 1

A




Supplementary Figure 1

B



C



Supplementary Figure 2

A

Full-length Fibulin-4 (F4)

mlpcasclpg slllwalllll llgsaspqds eepdsytect dgyewdpdsq
hcr**DVNECLT** **IPEACKGEMK** **CINHYGGYLC** **LPR**saavind lhgegppppv
ppaqhpnpcp pgyepddqds cvdvdecaqa lhdcrrpsqdc hnlpgsyqct
cpdgyr**KIGP** **ECVDIDECRY** Rycqhr**CVNL** **PGSFR**cqcep gfqlgpnnr**S**
CVDVNECDMG **APCEQRCFNS** **YGTFLCRCHQ** **GYELHRDGFS** **CSDIDECSYS**
SYLCQYRCIN **EPGRFSCHCP** **QGYQLLATR**l cqdidecesg ahqcseaqtc
vnfhgggyr**CV** **DTNRCVEPYI** **QVSENRLCP** **ASNPLCREQP** **SSIVHRYMTI**
TSERSVPADV **FQIQATSVYP** **GAYNAFQIRA** **GNSQGDFYIR** **QINNVSAMLV**
LARPVTGPRE **YVLDLEMVTM** **NSLMSYR**ass vlrltvfvga ytf

Truncated Fibulin-4 (tF4)

mlpcasclpg slllwalllll llgsaspqds eepdsytect dgyewdpdsq
hcr**DVNECLT** **IPEACKGEMK** **CINHYGGYLC** **LPR**saavind lhgegppppv
ppaqhpnpcp pgyepddqds cvdvdecaqa lhdcrrpsqdc hnlpgsyqct
cpdgyr**KIGP** **ECVDIDECRY** Rycqhr**CVNL** **PGSFR**cqcep gfqlgpnnr**S**
CVDVNECDMG **APCEQRCFNS** **YGTFLCRCHQ** **GYELHRDGFS** **CSDIDECSYS**
SYLCQYRcin epgr**F**SCHCP **QGYQLLATR**l cqdidecesg ahqcseaqtc
vnfhgggyr**CV** **DTNRCVEPYI** **QVSENRLCP** **ASNPLCR**eqp ssivhr**YMTI**
TSERSVPADV **FQIQATSVYP** **GAYNAFQIRA** **GNSQGDFYIR** qinnvsamlv
larpvtgpre yvldlemvtm nslmsyrass vlrltvfvga ytf


Supplementary Figure 2

B

Truncated fibrillin-1 (tFib-1)


mrrgrlleia lgftvllasy tshgadanle agnvketras rakrrGGGGH DALKGPNVCG SRYNAYCCPG WKTLPGGNQC
IVPICRHS CGFCSRPNMC TCPSGQIAPS CGSRsiqhn irCMNGGSCS DHCLCQKGY IGTHCGQPVC ESGCLNGGRc
vapnrCACTY GFTGPQ CERD yrTGPCFTVI SNQMCQGQLS GIVCTKqlcc atvgrAWGHP CEMCPAQPHP CRRGFIPNIR
tgacqdvdec qaipglcqqg ncintvgsfe ckcpaghkln evsqkcedid ecstipgice ggectntvss yfckCPPGFY
TSPDGTRCID VRPGYCYTAL TNGRCSNQLP QSITKMQCCC DAGRCWSPGV TVAPEMCPPIR atedfnklcs vpmvipgrpe
ypppplgpip pvlpvppgfp ppgqipvprp pveylypsre pprvlpvnt dycqlvrylc qngrciptpg syrcecnkgf
qldlrgecid vdeceknpc ggecinngs ytcqcrAGYQ STLTRtecrD IDECLQNGRI cnngrcintd gsfhcvcnag
fhvtrDGKNC EDMDECSIRn mclngmcine dgsfkCICKP GFQLASDGRy ckDINECETP GICMNGRCVN TDGYSRCECF
PGLAVGLDGR VCVDPHMRst cyggykrGQC IKPLFGAVTK secccastey afgepcqpcp aqnsaeyqal cssgpgmtsa
gsdinecald pdicpngice nlrqytkCIC NSGYEVDSTG KNCVDINECV LNSLLCDNGQ CRntpgsfvc tpcpGFIYKP
DLKtcedide cesspcingv ckNSPGSFIC ECSSESTLDP TKticietik GTCWQTVIDG RCEININGAT LKSQCCSSLG
AANGSPCTLC QVDPICGKgy srikgtqced idecevfpgv ckNGLCVNTR gsfkCQCPSG MTLDATGRIC LDIRLETCLF
RYEDEECTLP IAGRhrmdac ccsvgaawgt eeceecpmrN TPEYEELCPR gpgfatkEIT NGKPPFKdin eckMIPSLCT
HGKcrntigs fkrCDSGFA LDSEERnctd idecrispdl cgrGQCVNTP GDFECKcdeg yesgfmnmkN CMDIDECQRD
PLLCRggvch ntegsyrcec ppghqlspni sacidinece lsahlcpngr cvnligkYQC ACNPGYHSTP DRlfcvddide
csimggget fctnsegsye cscqpgfalm pdqrctdid ecednpiid ggqctnipge yrCLCYDGF MASEDMKtcvd
vnedlnpni clsgtcentk gsfichcdmg ysgkkgkTGC TDINECEIGA HNCQKHavct ntagsfkCSC SPGWIGDGIK
ctdldecsng thmcsqhadc kntmgsyrcl ckegytgdf tctdldecse nlnlcngqc lnapgyrCE CDMGFVPSAD
GKACEDIDEC SLPNICVFGT CHNLPGLFRC ECEIGYELDR sgnctdvne clqpttcisg ncvntpgsyi dcppdfeln
ptrvgcvdtr SGNCYLDIRP Rgdngdtacs neigvgvskA SCCC SLGKaw gtpcemcpav ntseykilcp ggegrfnpni
tviledidec qelpglcqqg kCINTFGSFQ CRCPYGYLN EDTRvcddvn ecetpgicgp gtcyntvgnv tcicppdymq
vnggnncmdm rrslycrnyy adnqtcdgel lfnmtkkmc csynigrwn kpceqcpips tdefatlcs qrgpfvidiy
tglpvdidec reipgveng vcinmvgsfr CECPVGFYFN DKllvcddid ecngpvcqr naecintags yrcdckpgyr
ftstgqcnr necqepnic shgqcidtvg sfyclchtgf ktnddqtmc1 dinecerdac gngtcrntig sfncrcnhgf
ilshnndcid vdecasngn lcrngqcint vgsfqcqne gyevapdgrt cvdineclle prkcapgtcq nldgsyrcic
ppgyslqnek cedidevee peicalgtcs ntegsfkclc pegfslssg rrcqdlrmsy cyakfeggkc sspksrnhsk
qeccalkge gwgdpcelcp tepdeafraqi cpygsgiiiv pddsavmdde ckepdvckhg qcintdgsyr cecpfgytla
gnecvdtdec svgnpcngt cknviggfec tceegfepgp mmtcedinec aqnp1lcafr cvntygsyec kcpvyvlre
drmkckdede ceegkhdte kqmecknlig tymeicgpy qrrpdgegev denecqtkpg icengrc1nt rgsytecend
gftaspnqde cldnregycf tevlqnmqi gssnrnpvtk secccdggrg wgphceicpf qgtvafkk1c phgrgfmtng
adideckvih dvrngec1v drgsyhck tgytpditgt scvdlne1c apkpcnfick ntegsyqcsc pkgylqedg
rsckdldeca tkqhncqflc vntig1ftck cpgftqhht scidnnects dinlcgskgi c1ntpgsftc ecqrgfsl1d
tgsscedvde cegnhrcqhg cqn1iggyrc scpgylqhy qwnqcvdene clsa1icgga schntlg1syk cmcpagf1ye
qfsggcqdin ecgsaqapcs ygcsnteggy lcgcp1gyfr igqghcvsgm gmgrgnpepp vs1gemddnsl speacyeck1
ngypkrgrkr rstnetdasn iedqsetean vslasw1vek taifafn1sh vsnkvrile1 lpaltt1tnh nryliesg1ne
dgffkinqke gisylhftkk kpvagtyslq isstplykkk elnqledkyd kdylsgelgd nlkmiq1vll h

Supplementary Figure 3




Supplementary Figure 4

A




B




Supplementary Figure 4

C




D




Supplementary Figure 5


A



B




C



Supplementary Figure 6

A



B

